Cell and Gene Therapy Market Region- Size, Share, Outlook, and Opportunity Analysis, 2022 – 2030
Genes can be discovered deep
within cells, which are the basic building elements of all living things. Genes
are tiny portions of DNA that hold genetic information as well as instructions
for the production of proteins, which aid in the construction and maintenance
of the body.
Global Cell and Gene Therapy Market Size Was Valued At US$ 15,580.3 Million
in 2022 and Is Expected To Witness A CAGR Of 24.7% Over the Forecast Period (2022
– 2030)
Over the forecast period, the
increasing prevalence of cardiovascular illness is expected to fuel growth in
the global Cell
and Gene Therapy Market . For example, according to a World Health
Organization report published in June 2021, an estimated 17.9 million people
died from cardiovascular illnesses in 2019, accounting for 32% of all global
deaths, with heart attacks and stroke accounting for 85% of these deaths
globally. In 2019, cardiovascular disorders were responsible for 38% of the 17
million premature deaths (before the age of 70) caused by no communicable
diseases worldwide.
Furthermore, to the same source,
by May 20, 2022, nearly 90% of COPD, Chronic obstructive pulmonary disease,
related fatalities worldwide in people under the age of 70 will occur in low-
and middle-income nations (LMIC)
Cell and gene therapy are
overlapping biomedical research topics with comparable therapeutic goals that
target DNA or RNA inside or outside the body. Both therapies try to change
genetic material in order to treat a disease. Gene therapy manipulates a
patient's cells using genetic material, or DNA, to treat an inherited or
acquired condition. To treat a disease, fresh cells are introduced into a
patient's body to develop, replace, or repair damaged tissue.
Cell and gene therapies are
classified into various therapeutic categories, including rare illnesses,
cancer, haematology, cardiology, ophthalmology, neurology, and others. Multiple
factors favour the existing Cell and
Gene Therapy Market, including rising cancer and other chronic disease
incidences, an increase in clinical trials, increased funding and investments
in the Cell and Gene Therapy Market, and a favourable regulatory environment
and FDA approvals for cell and gene therapy products.
The whole market has been divided
into four phases: phase me, phase II, phase III, and phase IV. Because the
majority of cell and gene therapies are in this phase of the clinical trial,
the phase II category led the global market in 2021, accounting for more than
52.8% of total revenue. The category is also predicted to grow at the quickest
rate over the forecast period, owing to increased R&D spending, an increase
in the number of industry-sponsored and non-industry-sponsored phase II clinical
studies, and the difficulties involved with phase II clinical trials.
Furthermore, the majority of Cell and Gene Therapy Market studies
are now failing to progress to the next level of research. This is followed by
contributes the most market share in the sector in 2021, the Phase 1 section is
likely to have a large proportion. The effective translation of medications
from non-clinical initiatives into First-in-Human clinical trials is one of the
primary reasons for the segment's growth. Despite the fact that the vast
majority of cell and gene therapy clinical trials are in stages I and II, the
number of trials now in the late phase, including phases III and IV, is
improving modestly. This is projected to boost market growth in the final
stages of clinical trials.
.webp)
.webp)
.webp)
Comments
Post a Comment